Randomized Controlled Trial Testing the Effectiveness of Adaptive "SMART" Stepped-Care Treatment for Adults With Binge-Eating Disorder Comorbid With Obesity

被引:47
|
作者
Grilo, Carlos M. [1 ]
White, Marney A. [2 ]
Masheb, Robin M. [1 ]
Ivezaj, Valentina [1 ]
Morgan, Peter T. [1 ]
Gueorguieva, Ralitza [3 ]
机构
[1] Yale Univ, Dept Psychiat, Sch Med, 300 George St 9th Floor, New Haven, CT 06511 USA
[2] Yale Univ, Dept Social & Behav Sci, Sch Publ Hlth, New Haven, CT 06511 USA
[3] Yale Univ, Dept Biostat, Sch Publ Hlth, New Haven, CT 06511 USA
基金
美国国家卫生研究院;
关键词
obesity; eating disorders; cognitive-behavioral therapy; binge eating; weight loss; COGNITIVE-BEHAVIORAL THERAPY; GUIDED SELF-HELP; WEIGHT-LOSS; RAPID RESPONSE; DOUBLE-BLIND; ORLISTAT; EFFICACY; OUTCOMES; SIBUTRAMINE; RISK;
D O I
10.1037/amp0000534
中图分类号
B84 [心理学];
学科分类号
04 ; 0402 ;
摘要
This randomized controlled trial (RCT) tested effectiveness of adaptive SMART stepped-care treatment to "standard" behavioral weight loss (BWL [standard]) for patients with binge-eating disorder (BED) and obesity. One hundred ninety-one patients were randomly assigned to 6 months of BWL (standard; n = 39) or stepped care (n = 152). Within stepped care, patients started with BWL for 1 month; treatment responders continued BWL, whereas nonresponders switched to cognitive-behavioral therapy (CBT), and patients receiving stepped care were additionally randomized to weight-loss medication or placebo (double-blind) for the remaining 5 months. Independent assessments were performed reliably at baseline, throughout treatment, and posttreatment. Intent-to-treat (ITT) analyses of remission rates (zero binges/month) revealed that BWL (standard) and stepped care did not differ (74.4% vs. 66.5%); within stepped care, remission rates ranged 40.0% to 83.3%, with medication significantly superior to placebo (overall) and among nonresponders switched to CBT. Mixed-models analyses of binge-eating frequency revealed significant time effects, but BWL (standard) and stepped care did not differ; within stepped care, medication was significantly superior to placebo and among nonresponders switched to CBT. Mixed models revealed significant weight loss, but BWL (standard; 5.1% weight-loss) and stepped care (5.8% weight-loss) did not differ; within stepped care (range = 0.4% to 8.8% weight-loss), medication was significantly superior to placebo and among both responders continued on BWL and nonresponders switched to CBT. In summary, BWL (standard) and adaptive stepped-care treatments produced robust improvements in binge eating and weight loss in patients with BED/obesity. Within adaptive stepped care, weight-loss medication enhanced outcomes for BED/obesity. Implications for clinical practice and future adaptive designs are offered.
引用
收藏
页码:204 / 218
页数:15
相关论文
共 50 条
  • [1] Testing a stepped care model for binge-eating disorder: a two-step randomized controlled trial
    Tasca, Giorgio A.
    Koszycki, Diana
    Brugnera, Agostino
    Chyurlia, Livia
    Hammond, Nicole
    Francis, Kylie
    Ritchie, Kerri
    Ivanova, Iryna
    Proulx, Genevieve
    Wilson, Brian
    Beaulac, Julie
    Bissada, Hany
    Beasley, Erin
    Mcquaid, Nancy
    Grenon, Renee
    Fortin-Langelier, Benjamin
    Compare, Angelo
    Balfour, Louise
    [J]. PSYCHOLOGICAL MEDICINE, 2019, 49 (04) : 598 - 606
  • [2] Randomized controlled trial testing behavioral weight loss versus multi-modal stepped-care treatment for binge eating disorder
    Grilo, C.
    [J]. EUROPEAN PSYCHIATRY, 2016, 33 : S163 - S163
  • [3] Lamotrigine in the treatment of binge-eating disorder with obesity: a randomized, placebo-controlled monotherapy trial
    Guerdjikova, Anna I.
    McElroy, Susan L.
    Welge, Jeffrey A.
    Nelson, Erik
    Kleck, Paul E.
    Hudson, James I.
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2009, 24 (03) : 150 - 158
  • [4] A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder
    Arnold, LM
    McElroy, SL
    Hudson, JI
    Welge, JA
    Bennett, AJ
    Keck, PE
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (11) : 1028 - 1033
  • [5] Atomoxetine in the treatment of binge-eating disorder: A randomized placebo-controlled trial
    McElroy, Susan L.
    Guerdjikova, Anna
    Kotwal, Renu
    Welge, Jeffrey A.
    Nelson, Erik B.
    Lake, Kathleen A.
    Keck, Paul E., Jr.
    Hudson, James I.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (03) : 390 - 398
  • [6] Zonisamide in the treatment of binge eating disorder with obesity: A randomized controlled trial
    McElroy, Susan L.
    Kotwal, Renu
    Guerdjikova, Anna I.
    Welge, Jeffrey A.
    Nelson, Erik B.
    Lake, Kathleen A.
    D'Alessio, David A.
    Keck, Paul E., Jr.
    Hudson, James I.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (12) : 1897 - 1906
  • [7] CARDIOVASCULAR DISEASE RISK REDUCTION IN PATIENTS WITH BINGE EATING DISORDER AND OBESITY: RANDOMIZED CONTROLLED TRIAL OF STEPPED-CARE VERSUS STANDARD BEHAVIORAL WEIGHT LOSS
    Grilo, C.
    [J]. ATHEROSCLEROSIS, 2015, 241 (01) : E19 - E19
  • [8] Stepped-care versus treatment as usual in panic disorder: A randomized controlled trial
    Kampman, Mirjam
    van Balkom, Anton J. L. M.
    Broekman, Theo
    Verbraak, Marc
    Hendriks, Gert-Jan
    [J]. PLOS ONE, 2020, 15 (08):
  • [9] EEG Neurofeedback in the Treatment of Adults with Binge-Eating Disorder: a Randomized Controlled Pilot Study
    Marie Blume
    Ricarda Schmidt
    Jennifer Schmidt
    Alexandra Martin
    Anja Hilbert
    [J]. Neurotherapeutics, 2022, 19 : 352 - 365
  • [10] EEG Neurofeedback in the Treatment of Adults with Binge-Eating Disorder: a Randomized Controlled Pilot Study
    Blume, Marie
    Schmidt, Ricarda
    Schmidt, Jennifer
    Martin, Alexandra
    Hilbert, Anja
    [J]. NEUROTHERAPEUTICS, 2022, 19 (01) : 352 - 365